Beam Therapeutics Inc $ 28.71 0.2 (0.68%)
Warning! GuruFocus has detected 1 Severe warning sign with BEAM. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for BEAM (Beam Therapeutics) from 2020 to Jul 02 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Beam Therapeutics stock (BEAM) PE ratio as of Jul 02 2020 is 0. More Details
Beam Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Beam Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:PTLA NAS:CRTX NAS:VCYT NAS:NGM NAS:KPTI NAS:BDTX NAS:ZNTL NAS:IMAB NAS:TBIO NAS:KNSA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Traded in other countries BEAM.USA
Address 26 Landsdowne Street, Cambridge, MA, USA, 02139
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.